當前位置：首頁 SCI期刊 SCIE期刊醫學中科院1區 JCRQ1 期刊介紹(非官網)

Journal Of Thoracic OncologySCIE

國際簡稱：J THORAC ONCOL 參考譯名：胸部腫瘤學雜志

中科院分區
1區
CiteScore分區
Q1
JCR分區
Q1

基本信息：: ISSN：1556-0864; E-ISSN：1556-1380; 是否OA：未開放; 是否預警：否; TOP期刊：是

出版信息：: 出版地區：UNITED STATES; 出版商：International Association for the Study of Lung Cancer; 出版語言：English; 出版周期：Monthly; 出版年份：2006; 研究方向：醫學-呼吸系統

評價信息：: 影響因子：21; H-index：113; CiteScore指數：36; SJR指數：7.879; SNIP指數：3.906

發文數據：: Gold OA文章占比：83.71%; 研究類文章占比：88.00%; 年發文量：100; 自引率：0.0392...; 開源占比：0.3402; 出版撤稿占比：0; 出版國人文章占比：0.14; OA被引用占比：0.1724...

投稿咨詢加急見刊

英文簡介期刊介紹 CiteScore數據中科院SCI分區 JCR分區發文數據常見問題

英文簡介Journal Of Thoracic Oncology期刊介紹

Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer, is the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. JTO emphasizes a multidisciplinary approach and includes original research reviews and opinion pieces. The audience includes epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists, nuclear medicine physicians, and research scientists with a special interest in thoracic oncology.

期刊簡介Journal Of Thoracic Oncology期刊介紹

《Journal Of Thoracic Oncology》自2006出版以來，是一本醫學優秀雜志。致力于發表原創科學研究結果，并為醫學各個領域的原創研究提供一個展示平臺，以促進醫學領域的的進步。該刊鼓勵先進的、清晰的闡述，從廣泛的視角提供當前感興趣的研究主題的新見解，或審查多年來某個重要領域的所有重要發展。該期刊特色在于及時報道醫學領域的最新進展和新發現新突破等。該刊近一年未被列入預警期刊名單，目前已被權威數據庫SCIE收錄，得到了廣泛的認可。

該期刊投稿重要關注點：

預計審稿時間：一般,3-6周
國際TOP期刊
醫學
ONCOLOGY
SCIE
中科院1區
非預警

Cite Score數據（2024年最新版）Journal Of Thoracic Oncology Cite Score數據

CiteScore：36
SJR：7.879
SNIP：3.906

學科類別	分區	排名	百分位
大類：Medicine 小類：Pulmonary and Respiratory Medicine	Q1	2 / 155	99%
大類：Medicine 小類：Oncology	Q1	11 / 404	97%

CiteScore 是由Elsevier(愛思唯爾)推出的另一種評價期刊影響力的文獻計量指標。反映出一家期刊近期發表論文的年篇均引用次數。CiteScore以Scopus數據庫中收集的引文為基礎，針對的是前四年發表的論文的引文。CiteScore的意義在于，它可以為學術界提供一種新的、更全面、更客觀地評價期刊影響力的方法，而不僅僅是通過影響因子(IF)這一單一指標來評價。

歷年Cite Score趨勢圖

中科院SCI分區Journal Of Thoracic Oncology 中科院分區

中科院 2023年12月升級版 綜述期刊：否 Top期刊：是

大類學科	分區	小類學科	分區
醫學	1區	ONCOLOGY 腫瘤學 RESPIRATORY SYSTEM 呼吸系統	1區 1區

中科院分區表 是以客觀數據為基礎，運用科學計量學方法對國際、國內學術期刊依據影響力進行等級劃分的期刊評價標準。它為我國科研、教育機構的管理人員、科研工作者提供了一份評價國際學術期刊影響力的參考數據，得到了全國各地高校、科研機構的廣泛認可。

中科院分區表 將所有期刊按照一定指標劃分為1區、2區、3區、4區四個層次，類似于“優、良、及格”等。最開始，這個分區只是為了方便圖書管理及圖書情報領域的研究和期刊評估。之后中科院分區逐步發展成為了一種評價學術期刊質量的重要工具。

歷年中科院分區趨勢圖

JCR分區Journal Of Thoracic Oncology JCR分區

2023-2024 年最新版

按JIF指標學科分區	收錄子集	分區	排名	百分位
學科：ONCOLOGY	SCIE	Q1	13 / 322	96.1%
學科：RESPIRATORY SYSTEM	SCIE	Q1	2 / 100	98.5%

按JCI指標學科分區	收錄子集	分區	排名	百分位
學科：ONCOLOGY	SCIE	Q1	12 / 322	96.43%
學科：RESPIRATORY SYSTEM	SCIE	Q1	2 / 101	98.51%

JCR分區的優勢在于它可以幫助讀者對學術文獻質量進行評估。不同學科的文章引用量可能存在較大的差異，此時單獨依靠影響因子(IF)評價期刊的質量可能是存在一定問題的。因此，JCR將期刊按照學科門類和影響因子分為不同的分區，這樣讀者可以根據自己的研究領域和需求選擇合適的期刊。

歷年影響因子趨勢圖

發文數據

2023-2024 年國家/地區發文量統計

國家/地區數量
USA1884
CHINA MAINLAND1205
Japan761
Canada487
England425
Spain425
Italy362
South Korea310
France305
Australia227

本刊中國學者近年發表論文

1、Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC: A Post Hoc Subgroup Analysis From PACIFIC
Author: Naidoo, Jarushka; Antonia, Scott; Wu, Yi-Long; Cho, Byoung Chul; Thiyagarajah, Piruntha; Mann, Helen; Newton, Michael; Faivre-Finn, Corinne

Journal: JOURNAL OF THORACIC ONCOLOGY. 2023; Vol. 18, Issue 5, pp. 657-663. DOI: 10.1016/j.jtho.2023.02.009
2、Tislelizumab Versus Docetaxel in Patients With Previously Treated Advanced NSCLC (RATIONALE-303): A Phase 3, Open-Label, Randomized Controlled Trial
Author: Zhou, Caicun; Huang, Dingzhi; Fan, Yun; Yu, Xinmin; Liu, Yunpeng; Shu, Yongqian; Ma, Zhiyong; Wang, Ziping; Cheng, Ying; Wang, Jie; Hu, Sheng; Liu, Zhihua; Poddubskaya, Elena; Disel, Umut; Akopov, Andrey; Dvorkin, Mikhail; Zheng, Wenjuan; Ma, Yiyuan; Wang, Yan; Li, Songzi; Yu, Cunjing; Rivalland, Gareth

Journal: JOURNAL OF THORACIC ONCOLOGY. 2023; Vol. 18, Issue 1, pp. 93-105. DOI: 10.1016/j.jtho.2022.09.217
3、NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC
Author: de Castro Jr, Gilberto; Rizvi, Naiyer A.; Schmid, Peter; Syrigos, Konstantinos; Martin, Claudio; Yamamoto, Nobuyuki; Cheng, Ying; Moiseyenko, Vladimir; Summers, Yvonne; Vynnychenko, Ihor; Lee, Sung Yong; Bryl, Maciej; Zer, Alona; Erman, Mustafa; Timcheva, Constanta; Raja, Rajiv; Naicker, Kirsha; Scheuring, Urban; Walker, Jill; Mann, Helen; Chand, Vikram; Mok, Tony

Journal: JOURNAL OF THORACIC ONCOLOGY. 2023; Vol. 18, Issue 1, pp. 106-119. DOI: 10.1016/j.jtho.2022.09.223
4、Adebrelimab (SHR-1316) in Combination With Chemotherapy as Perioperative Treatment in Patients With Resectable Stage II to III NSCLCs: An Open-Label, Multicenter, Phase 1b Trial
Author: Yan, Wanpu; Zhong, Wen-Zhao; Liu, Yan-Hui; Chen, Qixun; Xing, Wenqun; Zhang, Qin; Liu, Lunxu; Ge, Di; Chen, Keneng; Yang, Fan; Lin, Xiang; Song, Li; Shi, Wei; Wu, Yi-Long

Journal: JOURNAL OF THORACIC ONCOLOGY. 2023; Vol. 18, Issue 2, pp. 194-203. DOI: 10.1016/j.jtho.2022.09.222
5、First-Line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic NSCLC in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations
Author: Paz-Ares, Luis G.; Ciuleanu, Tudor-Eliade; Cobo, Manuel; Bennouna, Jaafar; Schenker, Michael; Cheng, Ying; Juan-Vidal, Oscar; Mizutani, Hideaki; Lingua, Alejo; Reyes-Cosmelli, Felipe; Reinmuth, Niels; Menezes, Juliana; Jassem, Jacek; Protsenko, Svetlana; Richardet, Eduardo; Felip, Enriqueta; Feeney, Kynan; Zurawski, Bogdan; Alexandru, Aurelia; Jimenez, Emmanuel de la Mora; Dakhil, Shaker; Lu, Shun; Reck, Martin; John, Thomas; Hu, Nan; Zhang, Xiaoqing; Sylvester, Judi; Eccles, Laura J.; Grootendorst, Diederik J.; Balli, David; Neely, Jaclyn; Carbone, David P.

Journal: JOURNAL OF THORACIC ONCOLOGY. 2023; Vol. 18, Issue 2, pp. 204-222. DOI: 10.1016/j.jtho.2022.10.014
6、PTEN Loss Expands the Histopathologic Diversity and Lineage Plasticity of Lung Cancers Initiated by Rb1/Trp53 Deletion
Author: Zhang, Letian; Zhu, Xiang; Liu, Congrong; Zhang, Bo; Zheng, Jie; Singh, Prashant K.; Bshara, Wiam; Wang, Jianmin; Gomez, Eduardo Cortes; Zhang, Xiaojing; Wang, Yanqing; Goodrich, David W.

Journal: JOURNAL OF THORACIC ONCOLOGY. 2023; Vol. 18, Issue 3, pp. 324-338. DOI: 10.1016/j.jtho.2022.11.019
7、Respiratory and Cardiometabolic Comorbidities and Stages I to III NSCLC Survival: A Pooled Analysis From the International Lung Cancer Consortium
Author: Garcia-Pardo, Miguel; Chang, Amy; Schmid, Sabine; Dong, Mei; Brown, M. Catherinen; Christiani, David; Tindel, Hilary Aurora; Brennan, Paul; Chen, Chu; Zhang, Jie; Ryan, Brid M.; Zaridze, David; Schabath, Matthew B.; Leal, Leticia Ferro; Reis, Rui Manuel; Tardon, Adonina; Fernandez-Tardon, Guillermo; Shete, Sanjay S.; Andrew, Angeline; Brenner, Hermann; Xu, Wei; Hung, Rayjean J.; Liu, Geoffrey

Journal: JOURNAL OF THORACIC ONCOLOGY. 2023; Vol. 18, Issue 3, pp. 313-323. DOI: 10.1016/j.jtho.2022.10.020
8、Defining Morphologic Features of Invasion in Pulmonary Nonmucinous Adenocarcinoma With Lepidic Growth: A Proposal by the International Association for the Study of Lung Cancer Pathology Committee
Author: Thunnissen, Erik; Beasley, Mary Beth; Borczuk, Alain; Dacic, Sanja; Kerr, Keith M.; Lissenberg-Witte, Birgit; Minami, Yuko; Nicholson, Andrew G.; Noguchi, Masayuki; Sholl, Lynette; Tsao, Ming-Sound; Le Quesne, John; Roden, Anja C.; Chung, Jin-Haeng; Yoshida, Akihiko; Moreira, Andre L.; Lantuejoul, Sylvie; Pelosi, Giuseppe; Poleri, Claudia; Hwang, David; Jain, Deepali; Travis, William D.; Brambilla, Elisabeth; Chen, Gang; Botling, Johan; Bubendorf, Lukas; Mino-Kenudson, Mari; Motoi, Noriko; Chou, Teh Ying; Papotti, Mauro; Yatabe, Yasushi; Cooper, Wendy; Invasion Working Group

Journal: JOURNAL OF THORACIC ONCOLOGY. 2023; Vol. 18, Issue 4, pp. 447-462. DOI: 10.1016/j.jtho.2022.11.026